The short answer
As of June 2026, GLP-1 weight-loss medication in India costs from about ₹1,290/month for generic semaglutide, about ₹5,660/month for branded Ozempic or Wegovy at the 0.25 mg starting dose (after the April 2026 price cut), and ₹14,000–₹17,500/month for Mounjaro (tirzepatide) at the common 2.5–5 mg doses. A supervised clinical program such as Kaivo adds a flat fee from ₹2,499/month, with the medicine bought separately from a licensed pharmacy at no markup.
A free 30-minute consult with an AIIMS-trained doctor sorts the medicine, the dose, and the real monthly cost for your case.
The full price table (June 2026)
Every figure below is the current Indian price after the two events that reshaped this market in 2026: the 20 March 2026 semaglutide patent expiry, and Novo Nordisk's April 2026 price cut. Medication prices are per month (roughly four weekly doses) at typical retail MRP; they vary by pharmacy, city and discount.
| Medication | Form | Cost / month (June 2026) | Notes |
|---|---|---|---|
| Generic semaglutide Natco, Dr Reddy's, Sun Pharma, Zydus, Cipla, Glenmark, Alkem |
Weekly injection (vial / pen) | From ₹1,290 | Cheapest by far; launched after the March 2026 patent expiry. Vials are cheapest; pen devices cost more. |
| Ozempic Novo Nordisk · semaglutide |
Weekly injection (pen) | ₹5,660 (0.25 mg) – ~₹9,000 (1 mg) | After the April 2026 cut (up to ~36%). Diabetes-indicated; weight-loss use off-label. |
| Wegovy Novo Nordisk · semaglutide |
Weekly injection (pen) | ₹5,660 (0.25 mg) – ₹16,400 (2.4 mg) | After cuts of ~37% (Nov 2025) and up to ~48% (Apr 2026). The obesity-indicated semaglutide. |
| Mounjaro Eli Lilly · tirzepatide |
Weekly injection (vial / KwikPen) | ₹14,000–₹17,500 (2.5–5 mg); up to ₹25,781 (15 mg) | Most effective for weight loss. Not affected by the semaglutide cuts, so the priciest innovator option. |
| Rybelsus Novo Nordisk · oral semaglutide |
Daily oral tablet | ~₹9,000–₹10,000 (14 mg) | Oral, needle-free, but milder weight effect. Diabetes-indicated; not part of the April injectable cut. |
Prices are indicative retail MRP as of June 2026 and vary by pharmacy, city, dose and discount. They are not a quote. Always confirm the current price with a licensed pharmacy.
Generic semaglutide — the cheapest option
The single biggest change of 2026 is generic semaglutide. When the Indian patent expired on 20 March 2026, more than a dozen manufacturers launched their own versions within days. The cheapest now sits at about ₹1,290 per month in vial form — a roughly 90% drop from the innovator pens of 2025. Brands in the market include Natco (Semanat), Dr Reddy's, Sun Pharma (Noveltreat), Zydus, Cipla, Glenmark and Alkem, in both vial and pen formats.
The trade-off is practical, not chemical: the active molecule is the same semaglutide, but the cheapest options are vials that need an insulin syringe and careful dosing, rather than a click pen. For most cost-conscious patients in maintenance, a CDSCO-approved generic from a credible manufacturer is the most sensible long-term choice — provided it is bought from a licensed pharmacy and dosed under supervision.
Ozempic and Wegovy after the April 2026 cut
Both are Novo Nordisk's semaglutide — Ozempic indicated for diabetes, Wegovy for obesity. To defend market share against the generics, Novo cut prices twice: about 37% on Wegovy in November 2025, then up to ~48% on Wegovy and ~36% on Ozempic in April 2026. The starting 0.25 mg dose of both now costs about ₹5,660/month. Ozempic rises to roughly ₹9,000 at the 1 mg dose; Wegovy climbs to about ₹16,400 at the full 2.4 mg maintenance dose. For someone who specifically wants the branded pen and its convenience, the gap to generics is now far smaller than it was a year ago.
Mounjaro — most effective, still premium
Mounjaro (tirzepatide) is a dual GIP/GLP-1 agonist and produces the deepest average weight loss of any option here — about 20.9% over 72 weeks in the SURMOUNT-1 trial, and it beat semaglutide head-to-head in SURMOUNT-5. It costs roughly ₹14,000–₹17,500/month for the common 2.5–5 mg doses, rising to about ₹20,625 at 7.5–10 mg and ₹25,781 at 12.5–15 mg. A useful quirk of the ladder: 10 mg costs the same as 7.5 mg, so stepping up there is effectively free. Because it is tirzepatide, Mounjaro was untouched by the semaglutide price war, which is why it is now the most expensive innovator choice.
For a deeper comparison of the two molecules, see Ozempic vs Mounjaro; and for the maintenance-cost play, switching from Mounjaro to generic semaglutide. One cost trap worth knowing before you climb the ladder: a stall at a lower dose is usually a titration signal, not a reason to panic-buy a higher pen — here's what to do when Mounjaro stalls before you pay for the next strength.
The real cost is more than the medicine
The price tag on the pen is the easy part. What actually determines whether GLP-1 therapy works — and whether it is safe — is the system around it: a doctor who picks the right molecule and dose (here's which doctor can prescribe it, and what a consult costs), a nutritionist who protects muscle and protein while you eat less, periodic bloodwork, and a plan for what happens when you stop. Skip that, and the most common outcomes are avoidable side effects, muscle loss, and weight regain.
This is where a program fee comes in. Kaivo charges a flat ₹2,499/month (Essential) or ₹4,499/month (Premium, with a quarterly 35-marker blood panel and a dedicated coach), and you buy the medication separately from a licensed pharmacy at no markup. So your realistic all-in monthly cost is medicine + program fee. On generic semaglutide, that can land well under ₹5,000 a month, fully supervised.
Start with a free consult. We'll tell you honestly whether GLP-1 is right for you, which medicine fits your budget, and what you'd pay end-to-end.
What it costs over a year
Annual cost depends almost entirely on which medicine you settle on for maintenance. A generic-semaglutide maintenance year can run roughly ₹15,000–₹50,000 in medication; a branded-semaglutide year (Ozempic/Wegovy) roughly ₹70,000–₹2 lakh depending on dose; and a Mounjaro year anywhere from ₹1.7 lakh to ₹3 lakh at higher doses. Many patients use the most effective drug to reach goal, then switch to a cheaper generic to hold it — a transition worth planning with your doctor well before you get there.
- Novo Nordisk India price revisions, April 2026 (Ozempic up to ~36%, Wegovy up to ~48%) and November 2025 (~37% on Wegovy), as reported by Reuters and Indian business press.
- Indian semaglutide patent expiry, 20 March 2026, and subsequent generic launches (Natco, Dr Reddy's, Sun Pharma, Zydus, Cipla, Glenmark, Alkem and others).
- Mounjaro (tirzepatide) Indian pricing, Eli Lilly launch (March 2025) and 2026 retail MRPs across major pharmacies.
- SURMOUNT-1 and SURMOUNT-5 clinical-trial weight-loss outcomes for tirzepatide and semaglutide.